BioVaxys Announces Positive Phase 1 Clinical Study Results with Maveropepimut-S (MVP-S) in Women with Hormone Receptor Positive/HER2 Negative (HR+/HER2-) Stage II-III Breast Cancer
Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or the "Company"), a clinical stage biotechnology company focused on developing advanced treatments in oncology, infectious disease, allergy, and other immune diseases based on its DPX™ antigen delivery and immune-educating technology platform, is very pleased to announce positive results from a phase 1 clinical study of maveropepimut-S ("MVP-S")...
2025-12-17 8:00 AM EST
BioVaxys Announces Sale of TAET Software Co
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2023) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") is pleased to announce that it has sold TAET Software Co. to 10402588 BC Ltd ("Purchaser"), a private company formed under the laws of British Columbia, in exchange for 500,000 shares of the Purchaser, with further potential future milestone payments totaling a maximum of 1,000,000 shares of the Purchaser and a maximum of USD$4,000,000 in...
2023-06-14 5:28 PM EDT
BioVaxys Announces Closing of Financing
Vancouver, British Columbia--(Newsfile Corp. - February 5, 2021) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or the "Company"), is pleased to announce that it has closed its previously announced non-brokered private placement (the "Private Placement"). Under the Private Placement, the Company has issued 4,417,647 units ("Units") at a price of $0.255 per Unit to certain strategic investors for total gross proceeds of approximately $1,126,500. Each Unit consists of one common share (a...
2021-02-05 7:00 AM EST
BioVaxys Announces Investment by Strategic Investor
Vancouver, British Columbia--(Newsfile Corp. - February 1, 2021) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or the "Company"), is pleased to announce a non-brokered private placement (the "Private Placement") consisting of 4,313,725 units ("Units") at a price of $0.255 per Unit for total gross proceeds of approximately $1,100,000. The Private Placement has been fully subscribed by one strategic investor. Each Unit consists of one common share (a "Common Share") and one whole Common...
2021-02-01 2:30 PM EST
BioVaxys Announces Form 211 Clearance For OTC Trading in the USA
Vancouver, British Columbia--(Newsfile Corp. - December 10, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that its submission of Form 211 to FINRA has been cleared and the Company's shares now qualify for trading in the United States on the OTC Pink Market under the symbol "LMNGF". The Company has also made an application for its common shares to be DTC eligible and expects to receive this designation within the next 30 days....
2020-12-10 8:00 AM EST
BioVaxys Provides Viral Vaccine Platform Program Update
Vancouver, British Columbia--(Newsfile Corp. - November 30, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or "the Company") is pleased to announce that it has received further data from its successfully completed murine model study demonstrating that immunizing mice with two doses of BVX-0320, its COVID-19 vaccine candidate, induced high levels of antibodies against the S1 fragment of the SARS-CoV-2 spike protein associated with inhibition of the binding of the virus to...
2020-11-30 8:00 AM EST
BioVaxys Announces 96.4 Percent Positive Antibody Immune Response Results from an In Vivo Murine Model Study of Its SARS-CoV-2 Vaccine
Vancouver, British Columbia--(Newsfile Corp. - November 11, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys") is pleased to announce that results from its preclinical animal study (also known as the "murine model study") of BVX-0320, its Covid-19 vaccine candidate, show that the vaccine elicits a positive immune response against the SARS-CoV-2 s-spike protein. Previous interim data from the study showed it possessed an excellent emerging tolerability profile with no...
2020-11-11 3:30 AM EST
BioVaxys Engages Advisor for Strategic Business Development
Vancouver, British Columbia--(Newsfile Corp. - November 9, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (FSE: 5LB) ("BioVaxys" or the "Company") is pleased to announce that it has engaged Encounter Technology Limited ("Encounter"), a company controlled by one of its directors, Mr. David Wang, for the purpose of advancing the Company's strategic business objectives in Asia, including commercial partnerships, research collaborations, and other such transactions. Under the terms of the...
2020-11-09 8:00 AM EST
BioVaxys Files Patent Application for Novel COVID-19 Diagnostic for T-Cell Immunity
Vancouver, British Columbia--(Newsfile Corp. - November 2, 2020) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys" or "the Company"), a world leader in haptenized protein vaccine research and development, announced today that it has filed a Provisional Patent Application with the U.S. Patent and Trademark Office entitled METHOD AND KIT FOR DETECTION OF CELL MEDIATED IMMUNE RESPONSE related to the potential development of a diagnostic for evaluating the presence or absence of a T-cell immune...
2020-11-02 8:00 AM EST
BioVaxys and The Ohio State University Enter into SARS-CoV-2 Research Collaboration to Study New Vaccine
Vancouver, British Columbia--(Newsfile Corp. - October 26, 2020) - BioVaxys Technology Corp. (CSE: BIOV), is pleased to announce that it has entered into a research collaboration with The Ohio State University ("OSU") for BioVaxys' SARS-CoV-2 vaccine candidate. OSU is a leading global academic research institute in the fight against SARS-CoV-2, with The Ohio State University Wexner Medical Center ("OSUWMC") also recently selected as a site for SARS2 multicenter clinical trials. The objective...
2020-10-26 8:00 AM EDT
BioVaxys Technology Corp. Announces Appointment of New Director
Vancouver, British Columbia--(Newsfile Corp. - October 21, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (formerly Lions Bay Mining Corp.) ("BioVaxys" or the "Company") is pleased to announce that David Wang and Darren Hermiston have been appointed as directors of the Company. Mr. Hermiston replaces Timothy Heenan, who has resigned to pursue other endeavors. The Company would like to sincerely thank Mr. Heenan for his contributions. The Board of Directors is now comprised of James Passin...
2020-10-21 8:00 AM EDT
BioVaxys Announces Interim Results from Preclincal Study of Its SARS-CoV-2 Vaccine
Vancouver, British Columbia--(Newsfile Corp. - October 14, 2020) - BioVaxys Technology Corp. (CSE: BIOV) ("BioVaxys") is pleased to announce that interim results from its ongoing preclinical animal study (also known as a "murine model study") of BXV-0320, its SARS-CoV-2 vaccine candidate, show a good emerging tolerability profile with no observed side effects or noteworthy clinical observations. Five weeks post-administration of BVX-0320 in the murine animal model, no toxicities have been...
2020-10-14 8:30 AM EDT
BioVaxys Technology Corp: Closing of Acquisition of BioVaxys Inc.
Vancouver, British Columbia--(Newsfile Corp. - October 6, 2020) - BioVaxys Technology Corp. (CSE: BIOV) (formerly Lions Bay Mining Corp.) ("BioVaxys" or the "Company") is pleased to announce the completion of its formerly announced acquisition of all of the securities BioVaxys Inc. (the "Transaction"). The Transaction was determined to be a "fundamental change" pursuant to the policies of the Canadian Securities Exchange (the "CSE") and the Company has re-classified itself from being a...
2020-10-06 8:00 AM EDT
Lions Bay Announces Closing of Final Tranche of Non-Brokered Private Placement and Provides Update on Completion of Production and Start of Dosing in BioVaxys' Preclincal Study Of SARS-CoV-2 Vaccine
Vancouver, British Columbia--(Newsfile Corp. - September 4, 2020) - Lions Bay Mining Corp. (CSE: LBM) ("Lions Bay" or the "Company") is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "Private Placement"). Under the final tranche (the "Final Tranche") of the Private Placement, the Company issued 2,954,582 units ("Units") at a price of $0.22 per Unit for total gross proceeds of approximately $650,008.00, and...
2020-09-04 12:49 PM EDT
Lions Bay Mining Announces Execution of Secured Lending Facility with BioVaxys Inc. and Production of Vaccine Candidate for Preclinical Study
Vancouver, British Columbia--(Newsfile Corp. - June 23, 2020) - Lions Bay Mining Corp. (CSE: LBM) (the "Company" or "Lions Bay") is pleased to announce that, following the execution of a Share Exchange Agreement with BioVaxys Inc. ("BioVaxys"), the Company has executed a USD$180,000 secured lending facility with BioVaxys, the proceeds of which will be used primarily for BioVaxys' preclinical studies of BVX-0320, a novel vaccine candidate for prevention of Covid-19 (the "BVX-0320 Vaccine...
2020-06-23 8:00 AM EDT
Lions Bay Announces Definitive Agreement for BioVaxys Acquisition and Concurrent Financing
Vancouver, British Columbia--(Newsfile Corp. - June 4, 2020) - Lions Bay Mining Corp. (CSE: LBM) (the "Company" or "Lions Bay") is pleased to announce that it has executed a Share Exchange Agreement (the "Definitive Agreement") with BioVaxys Inc. (previously known as BioVaxys LLC) ("BioVaxys"), a clinical-stage immunotherapeutics company developing vaccine platforms for SARS-CoV-2 and various cancers. Under the terms of transaction, the Company will acquire all of the issued and outstanding...
2020-06-04 9:00 AM EDT
Lions Bay Mining Announces Update on Acquisition Target BioVaxys Initiating A SARS-CoV-2 Vaccine Study and Definitive Agreement
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2020) - Lions Bay Mining Corp. (CSE: LBM) (the "Company" or "Lions Bay") is pleased to announce that it has been informed that BioVaxys LLC ( "BioVaxys") is in the process of preparing to launch a preclinical study of its proprietary vaccine for SARS-CoV-2, the virus that causes Covid-19. Lions Bay recently announced entering into a non-binding letter of intent dated April 17th, 2020 (the "LOI") to acquire BioVaxys, a private Delaware...
2020-05-14 8:00 AM EDT
Lions Bay Mining Confirms Forward Split and Record Date
Vancouver, British Columbia--(Newsfile Corp. - April 27, 2020) - Lions Bay Mining Corp. (CSE: LBM) the "Company" or "Lions Bay") confirms the Record Date (the "Record Date") of April 29th, 2020 for the upcoming two-for-one (2:1) stock split of the Company's common shares. Shareholders as of the Record Date will receive two new common shares for every one common share held (the "Stock Split"). The Company will use the "push-out" method to issue the additional common shares required to effect...
2020-04-27 8:00 AM EDT
Lions Bay Mining Announces Non-Binding LOI to Acquire BioVaxys LLC, a Clinical Stage Biopharma Company Developing Immunotherapeutic Vaccines for Life-threatening Viral Infections and Cancers
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2020) - Lions Bay Mining Corp. (CSE: LBM) (the "Company" or "Lions Bay") is pleased to announce it has entered into a non-binding letter of intent dated April 17th, 2020 (the "LOI") to acquire BioVaxys LLC ("BioVaxys") a private Delaware corporation (the "Proposed Transaction"). BioVaxys is a clinical stage biopharma company developing immunotherapeutic vaccines for life-threatening viral infections and various cancers. BioVaxys's...
2020-04-20 8:45 AM EDT
Lions Bay Announces Proposed Stock Split
Vancouver, British Columbia--(Newsfile Corp. - April 17, 2020) - Lions Bay Mining Corp. (CSE: LBM) (OTC PINK: LMNGF) ("Lions Bay" or the "Company") announces that it intends to subdivide its share capital on a 1 old share for 2 new shares basis (the "Stock Split"), subject to receipt of approval by the Canadian Securities Exchange (the "CSE"). In the event the Stock Split is completed, the outstanding common shares of the Company will increase from 10,727,428 to 21,454,856. The Company will...
2020-04-17 9:00 AM EDT